1. K-State home
  2. »College of Veterinary Medicine
  3. »Veterinary Health Center
  4. »Health Center Services
  5. »Clinical Trials
  6. »Evaluation of a multi-species probiotic for prevention of chemotherapy-induced gastrointestinal toxicity in dogs

Veterinary Health Center

Clinical Trials Office
Phone: 785-532-3046
ClinicalTrials@vet.k-state.edu

Veterinary Health Center
1800 Denison Ave.
Manhattan, KS 66506

For appointments or emergencies call:

Small Animal Desk
785-532-5690
785-532-4309 fax

Large Animal Desk
785-532-5700
785-532-4989 fax

vhc@vet.k-state.edu

Evaluation of a multi-species probiotic for prevention of chemotherapy-induced gastrointestinal toxicity in dogs

 

Purpose and Brief Study Description:

This study aims to evaluate the effects of probiotic administration on gastrointestinal (GI) toxicity in dogs with lymphoma receiving chemotherapy. You will also be asked to record a daily journal for the 14 days of the study noting stool quality and clinical signs; this journal will be returned at the last appointment.
If your dog takes part in the study, he/she will have blood drawn for measurement of red and white blood cell counts (CBC) prior to chemotherapy and 3 and 14 days after chemotherapy. We will also collect fecal samples on the day of enrollment prior to chemotherapy and 3 and 14 days after chemotherapy to look at bacterial population changes (dysbiosis index) after giving the medications. Your dog will receive either a daily probiotic medication or placebo for the 14 days of the study. We will also ask you to complete a survey about your dog’s clinical signs, stool quality, as well as his/her current diet and other medications. Completion of all treatments and return of the journal at the last appointment are required for inclusion into this study.

Follow-up visits:
Day 3 after chemotherapy: CBC and fecal sample collection
Day 14 after chemotherapy: CBC and fecal sample collection
Your dog will need to return to the Kansas State University Veterinary Health Center on days 3 and 14 for blood draw and fecal sample collection.

Eligibility:
Inclusion criteria:

  • Dogs with a confirmed diagnosis of non-gastrointestinal lymphoma, whose owners have elected for either multi-agent chemotherapy (CHOP-based protocol) or single-agent doxorubicin treatment.
  • Owner must be willing/able to administer a daily oral capsule to their dog.
  • Owner must be willing/able to return for rechecks 3 and 14 days after the initial chemotherapy dose
  • Owner must be willing/able to complete and return the daily clinical signs journal.

Exclusion criteria:

  • Dogs with chronic GI clinical signs (vomiting, diarrhea, novel antigen/ hydrolyzed diet or medications (e.g. prednisone) to control historical GI disease, intestinal thickening or layering loss on ultrasound).
  • Dogs who have received IV or oral antibiotics or probiotics in the last month.
  • Dogs who have received IV or oral anti-emetics in the last week.
  • Dogs who have previously received chemotherapy in the last year.

Client Compensation:

No direct compensation is provided and the owner is responsible for testing related to initial diagnosis and treatment for lymphoma, as recommended by the attending clinician. The study will cover the cost of complete blood cell count (CBC), samples of probiotic/placebo, and fecal analysis (dysbiosis index).

Contact Information:

Please contact Misty Bear, Clinical Trials Coordinator, for more information. Phone: (785)532-3046; email: ClinicalTrials@vet.k-state.edu